Daybreak

A look at India’s push to build a domestic chip-design industry and the policy rules blocking experienced returnee engineers. The podcast explores ownership restrictions, reimbursement risks, and why some startups opt for foreign funding. It also covers regulatory conflicts, manufacturing bottlenecks, and suggested fixes for the next phase of the scheme.

A deep dive into why health insurance payouts often fail when you most need them. Stories of claim denials, agent mis-selling, and hospitals keeping prices opaque. An examination of thin insurer margins, delayed reimbursements and investigative hold-ups. A look at how weak regulation and perverse incentives push up bills and frustrate policyholders.

New York startups turned political opinion into real-money bets and built billion-dollar prediction platforms. The story covers regulatory raids, rapid investor acceptance, and tense legal fights. It highlights anonymous large wagers that anticipated military strikes and the ethical risks of insider-informed trades. It examines why these markets matter to countries like India and who benefits from trading truth.

AI has upended search by replacing link lists with single synthesized answers that mention only a few brands. New strategies like answer engine optimization and generative engine optimization are emerging. Data shows AI-driven mentions convert far better, while authentic long-form content wins credibility. Brands scramble to diversify channels and engineer curiosity to stay visible.

A look at why a promised erotic mode for verified users never launched. A historical frame using Yoko Ono’s Cut Piece sets the stakes about audience agency. The rise and backlash of intimate chatbots like Replika and Character AI get examined. Legal setbacks for big tech and internal safety, age-gating, and moderation limits are highlighted.

Semaglutide goes generic in India, triggering a predicted 85-90% price plunge and reshaping competitive dynamics. Discussion covers how Eli Lilly overtook market share with aggressive pricing and stronger results. Novo's strategy pivots from drug defense to buying hospitals, data and care platforms. The episode examines partnerships, single‑specialty bets, and efforts to stay present across the patient journey.

A government push to train 50,000 Indian clinicians in AI and make them co-builders of health tech. Rapid enrolment and plans to scale AI literacy across healthcare roles. Tensions over data scarcity, legal accountability, and hospital hesitancy. Early prototypes include radiology, TB testing, and small-data models tailored to local clinical variation.

Mutasim Khan, an investigative reporter who exposed Bengaluru’s water crisis and the tanker economy, tells the story. He walks through how private tankers grew, why a government app flopped, and why apartments trust paid tankers over subsidised supply. He also uncovers conflicts where officials rented the same tankers they criticised and outlines community pushback and legal fights.

Conversation about fintech apps bundling AI assistants to aggregate accounts and surface hidden positions. Discussion of platforms and registered advisors using AI to generate personalised investment recommendations and portfolios. Talk of agentic AIs that can execute trades via logins or APIs and regulators building disclosure and responsibility rules. Debate on whether AI advice is inevitable given advisor shortages.

A deep dive into India's long-held bet on thorium and why its grand plan stalled. A new American-designed thorium fuel claims to work in Indian reactors and stirs debate. The story traces historical policy choices, a pivotal 2008 nuclear deal, technical challenges, and geopolitical trade offs tied to fuel supply and independence.